AVCNF
Price
$0.20
Change
-$0.01 (-4.76%)
Updated
Aug 14 closing price
Capitalization
22.34M
BIOYF
Price
$8.20
Change
-$0.05 (-0.61%)
Updated
Aug 14 closing price
Capitalization
93.29M
Interact to see
Advertisement

AVCNF vs BIOYF

Header iconAVCNF vs BIOYF Comparison
Open Charts AVCNF vs BIOYFBanner chart's image
Avicanna
Price$0.20
Change-$0.01 (-4.76%)
Volume$290.5K
Capitalization22.34M
BioSyent
Price$8.20
Change-$0.05 (-0.61%)
Volume$1.9K
Capitalization93.29M
AVCNF vs BIOYF Comparison Chart in %
Loading...
AVCNF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIOYF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVCNF vs. BIOYF commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVCNF is a Hold and BIOYF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (AVCNF: $0.19 vs. BIOYF: $8.20)
Brand notoriety: AVCNF and BIOYF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AVCNF: 89% vs. BIOYF: 737%
Market capitalization -- AVCNF: $22.34M vs. BIOYF: $93.29M
AVCNF [@Pharmaceuticals: Generic] is valued at $22.34M. BIOYF’s [@Pharmaceuticals: Generic] market capitalization is $93.29M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.73B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVCNF’s FA Score shows that 0 FA rating(s) are green whileBIOYF’s FA Score has 1 green FA rating(s).

  • AVCNF’s FA Score: 0 green, 5 red.
  • BIOYF’s FA Score: 1 green, 4 red.
According to our system of comparison, BIOYF is a better buy in the long-term than AVCNF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVCNF’s TA Score shows that 4 TA indicator(s) are bullish while BIOYF’s TA Score has 3 bullish TA indicator(s).

  • AVCNF’s TA Score: 4 bullish, 6 bearish.
  • BIOYF’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, BIOYF is a better buy in the short-term than AVCNF.

Price Growth

AVCNF (@Pharmaceuticals: Generic) experienced а -3.06% price change this week, while BIOYF (@Pharmaceuticals: Generic) price change was -1.13% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.25%. For the same industry, the average monthly price growth was +10.98%, and the average quarterly price growth was +78.05%.

Industries' Descriptions

@Pharmaceuticals: Generic (+4.25% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BIOYF($93.3M) has a higher market cap than AVCNF($22.3M). BIOYF YTD gains are higher at: 7.242 vs. AVCNF (-4.879). BIOYF has higher annual earnings (EBITDA): 11.3M vs. AVCNF (-1.47M). BIOYF has more cash in the bank: 17.4M vs. AVCNF (457K). AVCNF has less debt than BIOYF: AVCNF (73.5K) vs BIOYF (990K). BIOYF has higher revenues than AVCNF: BIOYF (38.3M) vs AVCNF (25.3M).
AVCNFBIOYFAVCNF / BIOYF
Capitalization22.3M93.3M24%
EBITDA-1.47M11.3M-13%
Gain YTD-4.8797.242-67%
P/E RatioN/A16.88-
Revenue25.3M38.3M66%
Total Cash457K17.4M3%
Total Debt73.5K990K7%
FUNDAMENTALS RATINGS
AVCNF vs BIOYF: Fundamental Ratings
AVCNF
BIOYF
OUTLOOK RATING
1..100
2453
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
26
Undervalued
PROFIT vs RISK RATING
1..100
10036
SMR RATING
1..100
10042
PRICE GROWTH RATING
1..100
4554
P/E GROWTH RATING
1..100
10057
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BIOYF's Valuation (26) in the null industry is somewhat better than the same rating for AVCNF (62). This means that BIOYF’s stock grew somewhat faster than AVCNF’s over the last 12 months.

BIOYF's Profit vs Risk Rating (36) in the null industry is somewhat better than the same rating for AVCNF (100). This means that BIOYF’s stock grew somewhat faster than AVCNF’s over the last 12 months.

BIOYF's SMR Rating (42) in the null industry is somewhat better than the same rating for AVCNF (100). This means that BIOYF’s stock grew somewhat faster than AVCNF’s over the last 12 months.

AVCNF's Price Growth Rating (45) in the null industry is in the same range as BIOYF (54). This means that AVCNF’s stock grew similarly to BIOYF’s over the last 12 months.

BIOYF's P/E Growth Rating (57) in the null industry is somewhat better than the same rating for AVCNF (100). This means that BIOYF’s stock grew somewhat faster than AVCNF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVCNFBIOYF
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
48%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
46%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
44%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
47%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
38%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
39%
Advances
ODDS (%)
Bullish Trend 3 days ago
82%
N/A
Declines
ODDS (%)
Bearish Trend 8 days ago
87%
Bearish Trend 2 days ago
42%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
53%
Aroon
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 2 days ago
44%
View a ticker or compare two or three
Interact to see
Advertisement
AVCNF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIOYF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DHLGY48.880.35
+0.72%
Deutsche Post AG
BCVVF9.00N/A
N/A
BOC Aviation Ltd.
PGUCY4.50N/A
N/A
Prosegur Cash
SPGX0.30N/A
N/A
Sustainable Projects Group Inc.
BLMH0.65-0.04
-5.98%
Blum Holdings Inc.

AVCNF and

Correlation & Price change

A.I.dvisor tells us that AVCNF and PRFX have been poorly correlated (+20% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AVCNF and PRFX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVCNF
1D Price
Change %
AVCNF100%
-2.28%
PRFX - AVCNF
20%
Poorly correlated
-4.93%
ARSUF - AVCNF
12%
Poorly correlated
N/A
BSPK - AVCNF
9%
Poorly correlated
N/A
APNHY - AVCNF
7%
Poorly correlated
N/A
BKUH - AVCNF
5%
Poorly correlated
N/A
More

BIOYF and

Correlation & Price change

A.I.dvisor tells us that BIOYF and BUDZ have been poorly correlated (+6% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BIOYF and BUDZ's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIOYF
1D Price
Change %
BIOYF100%
-0.05%
BUDZ - BIOYF
6%
Poorly correlated
-13.11%
AVCNF - BIOYF
1%
Poorly correlated
-2.28%
APNHY - BIOYF
0%
Poorly correlated
N/A
BSPK - BIOYF
0%
Poorly correlated
N/A
BIOVF - BIOYF
0%
Poorly correlated
N/A
More